Completed PHASE2 INTERVENTIONAL 2-arm NCT03968302

ADDITION OF BISMUTH TO THE STANDARD TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION

ADDITION OF BISMUTH TO THE STANDARD TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION: A RANDOMIZED CONTROLLED STUDY

Sponsor: Ziauddin University

Conditions Helicobacter Pylori Infection

Interventions ARM A Triple therapy for helicobacter pylori ARM B Quadruple therapy for helicobacter pylori

Updated 4 times since 2019 Last updated: May 28, 2019 Started: Jun 1, 2018 Primary completion: May 15, 2019 Completion: May 15, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Helicobacter Pylori Infection, this trial is completed. The trial is conducted by Ziauddin University and has accumulated 4 data snapshots since 2018. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2019 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ziauddin University

Data source: Ziauddin University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Karachi, Pakistan